blockchain crypto currencies, searches

Borui Medicine: Carboprost injection is planned to win the bid for the national centralized drug procurement. Borui Medicine announced that in the tenth batch of national centralized drug procurement in which Borui Pharmaceutical, a wholly-owned subsidiary, participated, carboprost tromethamine injection is planned to win the bid. This product is mainly used for 13-20 weeks pregnant abortion and postpartum hemorrhage. The specification is 1 ml: 250μ g, and the proposed bid price is 16.96 yuan/piece. In the first year, the agreed purchase base is 220,400 pieces, which are mainly supplied to Henan, Hubei, Guangxi, Shaanxi, Gansu, Ningxia and other provinces. If the contract is finally selected and signed, it will help the product to quickly open the domestic market and enhance the market share and brand influence of the company. The product obtained the drug registration certificate in March 2024, and has not yet generated sales revenue.Pacific Securities: Goldwind Technology's performance is expected to achieve rapid growth, with the first "buy" rating. Pacific Securities Research Report pointed out that with the profit recovery of wind turbine business and the contribution of wind farm investment and development and wind power service business, Goldwind Technology's (002202.SZ) performance is expected to achieve rapid growth. The first coverage gives a "buy" rating. Goldwind Technology has ranked first in the domestic wind power market for 13 consecutive years since 2011; However, in recent years, under the strong competitive pressure of wind turbine enterprises after the second line, their market share has declined. In the future, with the increase of market concentration, Goldwind Technology, as a leader, is expected to increase its share. At the end of the third quarter of 2024, the company's external order volume was 41.38GW, and sufficient in-hand order volume supported its share increase.InBev Cloud released a number of intelligent computing products. On December 13th, InBev Mathematics Department officially released a brand-new series of intelligent computing products and services, covering the construction and operation of intelligent computing centers, GPU container services, advanced computing laboratories and industrial incubators, and put forward the innovative index of "effective computing cost per unit" for the first time in the industry, so as to promote the intelligent computing industry to a high-efficiency and diversified development paradigm.

Market News: Lotte Chemical will suspend the Johor plant to reduce losses.European Central Bank Management Committee Muller: It is expected that Europe will recover slowly.Market news: Israel said that the IDF will stay on the Syrian side of Mount Hermon for several months.

Bank of Communications: Wang Wenjin resigned as business director. Due to job transfer, Wang Wenjin has submitted a written report to the board of directors of the company and resigned as business director (corporate and institutional business). His resignation will take effect on December 13, 2024.Huatong Co., Ltd.: The sales revenue of live pigs in November was 410 million yuan. Huatong Co., Ltd. announced that in November 2024, the company sold 201,000 pigs, including 10,600 piglets. The sales revenue of live pigs reached 410 million yuan, an increase of 20.56% from the previous month. The average selling price of commercial pigs was 16.5 yuan/kg, down 4.07% from October. In addition, the number of chickens sold in November was 1,205,900, a decrease of 47.69% from the previous month and a year-on-year increase of 19.79%. Chicken sales revenue was 20,213,700 yuan, an increase of 23.65% from the previous month. Sales data are unaudited for investors' reference.Yiling Pharmaceutical Co., Ltd.: The application for clinical trial of Lianhua Yuping Granule was approved, and Yiling Pharmaceutical announced that Beijing Yiling, a wholly-owned subsidiary, received the Notice of Approval for Clinical Trial of Drugs approved and issued by National Medical Products Administration on December 12, 2024, and agreed to carry out clinical trial of Lianhua Yuping Granule for qi deficiency syndrome of common cold.